Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the H eart F ailure A ssociation ( HFA ), the E uropean A ssociation of C ardiovascular I maging ( EACVI ) and the Cardio‐Oncology C ouncil of the E uropean S ociety of C ardiology ( ESC ) - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue European Journal of Heart Failure Année : 2020

Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the H eart F ailure A ssociation ( HFA ), the E uropean A ssociation of C ardiovascular I maging ( EACVI ) and the Cardio‐Oncology C ouncil of the E uropean S ociety of C ardiology ( ESC )

1 Vilnius University [Vilnius]
2 UK - Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic]
3 La Paz University Hospital
4 St Bartholomew's Hospital (London)
5 NKUA - National and Kapodistrian University of Athens
6 Imperial College London
7 Medizinische Universität Wien = Medical University of Vienna
8 MASCOT (UMR_S_942 / U942) - Marqueurs cardiovasculaires en situation de stress
9 Hôpital Lariboisière-Fernand-Widal [APHP]
10 UCY - University of Cyprus [Nicosia]
11 University of Naples Federico II = Università degli studi di Napoli Federico II
12 Georg-August-University = Georg-August-Universität Göttingen
13 Uppsala University
14 LSMU - Lithuanian University of health Sciences
15 UNIBE - Universität Bern / University of Bern
16 Royal Brompton Hospital
17 University of Groningen [Groningen]
18 DZHK - German Center for Cardiovascular Research
19 TAU - Tel Aviv University
20 CHSH - 'Clalit' Health Services Haifa
21 University of Bristol [Bristol]
22 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
23 Universitair Ziekenhuis [Brussels, Belgium]
24 Hirslanden Medical Center
25 Sechenov First Moscow State Medical University
26 CIC 1418 - CIC - HEGP
27 PARCC (UMR_S 970/ U970) - Paris-Centre de Recherche Cardiovasculaire
28 Federico II University Hospital
29 CHU-Liège - Centre Hospitalier Universitaire de Liège
30 LUMC - Leiden University Medical Center
31 Baker Heart and Diabetes Institute (AUSTRALIA)
32 Emergency Institute for Cardiovascular Diseases “Prof. Dr. C.C. Iliescu” [Bucharest, Romania]
33 UMPCD - University of Medicine and Pharmacy “Carol Davila” Bucharest
34 LIU - Linköping University
35 Universiteit Utrecht / Utrecht University [Utrecht]
36 UHasselt - Hasselt University
37 Ospedale "Guglielmo da Saliceto"
38 UNIPR - Università degli studi di Parma = University of Parma
39 MHH - Medizinische Hochschule Hannover = Hannover Medical School
40 Maastricht University [Maastricht]
41 QMUL - Queen Mary University of London
42 KU Leuven - Catholic University of Leuven = Katholieke Universiteit Leuven
43 Unibas - Université de Bâle = University of Basel = Basel Universität
44 Universidade do Porto = University of Porto
45 University hospital of Zurich [Zurich]
46 Ramon & Cajal University Hospital
47 UAH - Universidad de Alcalá - University of Alcalá
48 ISC - Instituto de Salud Carlos III [Madrid]
49 IRCCS San Raffaele [Rome, Italy]
50 University of London [London]
51 University of Belgrade [Belgrade]
52 Oslo University Hospital [Oslo]
53 UiO - University of Oslo
Vassilis Barberis
  • Fonction : Auteur
Riccardo Asteggiano
  • Fonction : Auteur

Résumé

Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position statement examines the role of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging and computed tomography in the management of cancer patients. The Imaging and Cardio-Oncology Study Groups of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the ESC have evaluated the current evidence for the value of modern CV imaging in the cardio-oncology field. The most relevant echocardiographic parameters, including global longitudinal strain and three-dimensional ejection fraction, are proposed. The protocol for baseline pre-treatment evaluation and specific surveillance algorithms or pathways for anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor tyrosine kinase inhibitors, BCr-Abl tyrosine kinase inhibitors, proteasome inhibitors and immune checkpoint inhibitors are presented. The indications for CV imaging after completion of oncology treatment are considered. The typical consequences of radiation therapy and the possibility of their identification in the long term are also summarized. Special populations are discussed including female survivors planning pregnancy, patients with carcinoid disease, patients with cardiac tumours and patients with right heart failure. Future directions and ongoing CV imaging research in cardio-oncology are discussed.

Dates et versions

hal-03676837 , version 1 (24-05-2022)

Identifiants

Citer

Jelena Čelutkienė, Radek Pudil, Teresa López‐fernández, Julia Grapsa, Petros Nihoyannopoulos, et al.. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the H eart F ailure A ssociation ( HFA ), the E uropean A ssociation of C ardiovascular I maging ( EACVI ) and the Cardio‐Oncology C ouncil of the E uropean S ociety of C ardiology ( ESC ). European Journal of Heart Failure, 2020, 22 (9), pp.1504-1524. ⟨10.1002/ejhf.1957⟩. ⟨hal-03676837⟩
33 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More